Valuation: Glaukos Corporation

Market Cap 14.04B 12.79B 11.78B 10.72B 20.11B 1,300B 21.14B 143B 57B 710B 52.68B 51.57B 2,229B P/E 2026 *
-949x
P/E 2027 * 181x
Enterprise Value 13.89B 12.65B 11.66B 10.61B 19.9B 1,286B 20.91B 142B 56.4B 703B 52.12B 51.02B 2,205B EV / Sales 2026 *
17.8x
EV / Sales 2027 * 13.7x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.33%
1 week-3.42%
Current month-0.12%
1 month+36.83%
3 months+28.35%
6 months+65.00%
Current year+110.18%
1 week 231.61
Extreme 231.61
250.61
1 month 173.08
Extreme 173.075
255.18
Current year 93.96
Extreme 93.96
255.18
1 year 93.96
Extreme 93.96
255.18
3 years 59.22
Extreme 59.22
255.18
5 years 33.33
Extreme 33.33
255.18
10 years 23.08
Extreme 23.075
255.18
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
Director of Finance/CFO 50 04/05/2017
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Exercice

Director

7,500 0.0131%
30/10/26 Don

Director

-4,764 0.0083%
30/10/26 Exercice

Executive/Senior Manager

70,374 0.1227%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%-3.42%+149.28%+271.26% 14.04B
-0.84%-5.09%-16.92%+1.78% 178B
-0.67%-2.84%+0.59%+32.97% 122B
-0.98%+0.12%-14.00%+7.16% 118B
-1.24%-4.25%-43.89%-1.12% 88.1B
-0.63%-5.55%-6.35%+73.06% 64.71B
+0.05%-2.41%+12.24%-8.94% 57.96B
-1.95%-3.98%-1.91%+42.98% 53.28B
-2.91%-4.35%-0.82%+38.03% 47.8B
-1.64%+1.50%+2.30%-1.14% 35.65B
Average -1.11%-2.68%+8.05%+45.60% 78B
Weighted average by Cap. -1.03%-2.97%-7.85%+22.02%

Financials

2026 *2027 *
Net sales 781M 711M 655M 596M 1.12B 72.28B 1.17B 7.97B 3.17B 39.48B 2.93B 2.87B 124B 1B 914M 842M 766M 1.44B 92.92B 1.51B 10.25B 4.07B 50.75B 3.77B 3.69B 159B
Net income -17.36M -15.82M -14.57M -13.26M -24.87M -1.61B -26.14M -177M -70.5M -878M -65.15M -63.78M -2.76B 76.26M 69.46M 64M 58.22M 109M 7.06B 115M 779M 310M 3.86B 286M 280M 12.1B
Net Debt -149M -136M -125M -114M -214M -13.82B -225M -1.52B -606M -7.55B -560M -548M -23.69B -298M -271M -250M -227M -426M -27.57B -448M -3.04B -1.21B -15.06B -1.12B -1.09B -47.25B
Projected Income Statement - Annual - Glaukos Corporation
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
20/11/26 US$237.31 -0.33% 1,089,561
19/11/26 US$238.10 +2.15% 746,186
18/11/26 US$233.08 -4.18% 1,132,346
17/11/26 US$243.25 -0.67% 718,403
16/11/26 US$244.88 -0.34% 865,459
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Glaukos Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
237.31USD
Average target price
243.85USD
Spread / Average Target
+2.75%
  1. Stock Market
  2. Stocks
  3. GKOS Stock